CSS
MLYS icon

Cubist Systematic Strategies’s Mineralys Therapeutics MLYS Stock Holding History

Cubist Systematic Strategies’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,823
Closed -$36.4K – 3631
2024
Q1 		$36.4K Sell
2,823
-14,574
-84% -$180K ﹤0.01% 3420
2023
Q4 		$150K Buy
17,397
+16,912
+3,487% +$133K ﹤0.01% 3089
2023
Q3 		$4.61K Buy
+485
New +$6.32K ﹤0.01% 3175
2023
Q2 		– Sell
-10,227
Closed -$160K – 3997
2023
Q1 		$160K Buy
+10,227
New +$172K ﹤0.01% 3316

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Cubist Systematic Strategies's MLYS Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Mineralys Therapeutics (MLYS) in Q2 2024, closing a stake of 2,823 shares — an estimated $36.4K sold.

Cubist Systematic Strategies first reported a position in MLYS in Q1 2023 and held it in 4 quarters. The position peaked at $160K in Q1 2023. 94 funds tracked by Wall St. Rank hold MLYS as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Mineralys Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2,823 Mineralys Therapeutics shares in Q2 2024, an estimated $36.4K.
  • Cubist Systematic Strategies first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 4 quarters.
  • Cubist Systematic Strategies's Mineralys Therapeutics position peaked at $160K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.